Moskowitz R W
Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Curr Rheumatol Rep. 2000 Dec;2(6):466-71. doi: 10.1007/s11926-000-0022-x.
As evidenced by publication of a new set of guidelines for the treatment of osteoarthritis (OA) by the American College of Rheumatology after only 5 years, modalities available for the management of OA have undergone significant changes. New therapeutic approaches include the use of cyclo-oxygenase-2 inhibitors, and intra-articular hyaluronans (HA). HA, found in a number of body tissues, is altered in the presence of osteoarthritis with decreased molecular weight and concentration resulting in impaired viscoelasticity. Hyaluronan preparations have been shown to decrease pain and increase function in patients with osteoarthritis of the knee. Mechanisms of therapeutic effect include restoration of more normal synovial fluid with improved viscoelasticity, effects on cartilage biosynthesis and degradation, anti-inflammatory effects, and direct analgesic effects. Studies in animal models, and preliminary studies in humans suggest that hyaluronans may have a structure-modifying effect in OA. Hyaluronans represent a substantive addition to the therapeutic armamentarium in osteoarthritis.
仅5年后美国风湿病学会就发布了一套新的骨关节炎(OA)治疗指南,这表明可用于OA管理的方法已发生了重大变化。新的治疗方法包括使用环氧化酶-2抑制剂和关节内注射透明质酸(HA)。HA存在于多种身体组织中,在骨关节炎患者体内会发生改变,分子量和浓度降低,导致粘弹性受损。透明质酸制剂已被证明可减轻膝骨关节炎患者的疼痛并改善功能。治疗作用机制包括恢复具有更好粘弹性的更正常滑液、对软骨生物合成和降解的影响、抗炎作用以及直接止痛作用。动物模型研究和人体初步研究表明,透明质酸可能对OA具有结构改变作用。透明质酸是骨关节炎治疗手段中的一项重要补充。